
1 **TITLE: Clinical and Economic impact of updated Fall 2023 COVID-19 vaccines in the**
2 **Immunocompromised Population in Canada**

3

4 Authors: Amy Lee,¹ Kavisha Jayasundara,² Michele Kohli,¹ Michael Maschio,¹ Kelly Fust,¹ Keya
5 Joshi,³ Nicolas van de Velde,³ and Ekkehard Beck³

6 ¹Quadrant Health Economics Inc; 92 Cottonwood Crescent, Cambridge, Ontario, Canada

7 ²Moderna BioPharma Canada, Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC,
8 Canada

9 ³Moderna Inc; 200 Technology Square, Cambridge, MA, United States

10

11 Corresponding author

12 Amy Lee, PhD; Quadrant Health Economics Inc; 92 Cottonwood Crescent,
13 Cambridge, ON N1T 2J1, Canada

14 **ABSTRACT**

15 Background: Immunocompromised (IC) individuals are at increased risk of COVID-19 infection-
16 related severe outcomes. Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines are available
17 in Canada, and differences in vaccine effectiveness (VE) have been found between the two in IC
18 individuals. The objective of this analysis was to compare the clinical and economic impact of a
19 Moderna XBB.1.5 updated COVID-19 mRNA Fall 2023 vaccine to a Pfizer-BioNTech XBB.1.5
20 updated COVID-19 mRNA Fall 2023 vaccine in Canadian IC individuals aged ≥ 18 years.

21 Methods: A static decision-analytic model estimated the number of COVID-19 infections,
22 hospitalizations, deaths, and resulting quality-adjusted life years (QALYs) over a one-year time
23 horizon (September 2023-August 2024) in the Canadian IC adult population ($n=894,580$). Costs
24 associated with COVID-19 infection were estimated from health care and societal perspectives.
25 The predicted VE of the updated Moderna vaccine was based on prior variant versions, which
26 were well-matched to the circulating variant. Pfizer-BioNTech VE was calculated based on a
27 meta-analysis of comparative effectiveness between both vaccines (relative risk for Moderna
28 vaccine: infection=0.85 [95%CI 0.75-0.97], hospitalization=0.88 [95%CI 0.79-0.97]). The model
29 combined VE estimates with COVID-19 incidence and probability of COVID-19 related severe
30 outcomes. Sensitivity analyses tested the impact of uncertainty surrounding incidence,
31 hospitalization and mortality rates, costs, and QALYs.

32 Results: Given the expected higher VE against infection and hospitalizations with the Moderna
33 Fall 2023 vaccine, its use is predicted to prevent an additional 2,411 infections (3.6%), 275
34 hospitalizations (3.7%), and 47 deaths (4.0%) compared to the Pfizer-BioNTech Fall 2023
35 vaccine, resulting in 330 QALYs gained, and savings of \$7.4M in infection treatment costs, and
36 \$0.9M in productivity loss costs. Results were most sensitive to variations in VE parameters,

37 specifically the relative risk of infection and hospitalizations between the vaccines, and waning
38 rates.

39 Conclusions: If the Moderna and Pfizer-BioNTech Fall 2023 vaccines protect against infection
40 and hospitalizations similar to previous vaccines, using the Moderna Fall 2023 vaccine would
41 result in substantial public health benefits in IC individuals, as well as provide health care and
42 societal cost savings.

43

44 Keywords: coronavirus vaccine, economic modeling, decision analysis, coronavirus
45 hospitalization, vaccine effectiveness, Canada

46 INTRODUCTION

47 On May 5, 2023, the World Health Organization (WHO) declared that COVID-19 is no longer
48 considered a public health emergency, but an ongoing health issue.¹ It recommended that
49 vaccination efforts continue, particularly in high-priority groups. As the SARS-CoV-2 virus
50 continues to evolve, there is an emphasis on updating the vaccines to target the current variants
51 of concern. On September 12, 2023, the Canadian National Advisory Committee on Immunization
52 (NACI) amended their guidance on the use of COVID-19 vaccines in the Fall of 2023.²

53 The updated Canadian guidance advises the use of an XBB.1.5-containing COVID-19 vaccine,
54 with particular importance placed on those at increased risk of COVID-19 severe disease, such
55 as those with underlying medical conditions, including those with primary immunodeficiency
56 diseases, malignancies or who use immunosuppressive medications.³

57 Compromised immune systems can be due to genetic defects or conditions that suppress the
58 immune system,⁴ such as solid tumours or hematologic malignancies, solid organ or
59 hematopoietic stem cell transplants, chronic kidney disease on dialysis, human immunodeficiency
60 virus (HIV), and chronic use of immunosuppressive or immunomodulatory medications.⁵ These
61 individuals are considered to be moderately to severely immunocompromised by the Canadian
62 National Advisory Committee on Immunization (NACI),⁵ and are at greater risk of hospitalizations,
63 and mortality from infectious diseases, including COVID-19.^{4,6-9} It is therefore important to
64 increase their immune response against SARS-CoV-2 through vaccination.

65 The protective response mounted by immunocompromised (IC) individuals to the COVID-19
66 vaccinations is decreased compared to their immunocompetent counterparts. In a prospective
67 cohort study conducted at Kaiser Permanente Southern California, Tseng et al., (2023) found the
68 adjusted vaccine effectiveness (VE) for the general population of the Moderna BA.4/BA.5 bivalent
69 vaccine (mRNA-1273.222) against hospitalization was 82.8%, but reduced to 71.8% in those that

70 were IC.¹⁰ Additionally, similar to the general population,¹¹⁻¹⁵ VE has been found to differ between
71 the two mRNA COVID-19 vaccines in the IC population. Although both Moderna and Pfizer-
72 BioNTech COVID-19 vaccines utilize mRNA technology, the formulation, including the type of
73 nanoparticles used for the mRNA delivery system, and dosage of each vaccine differ.¹⁶⁻¹⁹ A
74 systematic literature review and meta-analysis based on 17 studies by Wang et al., (2023) found
75 that in the IC population, the Moderna mRNA-1273 vaccine to be associated with significantly
76 lower risk of COVID-19 infection, hospitalizations, and deaths compared to the Pfizer-BioNTech
77 BNT162b2 vaccine (relative risk for infection = 0.85 [95% CI 0.75-0.97]; hospitalization = 0.88
78 [95% CI 0.79-0.97]).²⁰

79 Given the approval of the recently updated COVID-19 vaccines in Canada for both Moderna and
80 Pfizer-BioNTech,^{21,22} the question arises on whether and to which extend there may be clinical or
81 economic differences between the use of these two mRNA vaccines in this vulnerable IC
82 population. The objective of this analysis was to estimate the clinical and economic impact of a
83 Moderna XBB.1.5 updated COVID-19 mRNA Fall 2023 vaccine (Moderna Fall 2023 vaccine)
84 compared to a Pfizer-BioNTech XBB.1.5 updated COVID-19 mRNA Fall 2023 vaccine (Pfizer-
85 BioNTech Fall 2023 vaccine) in IC individuals aged 18 years over a one-year time horizon from
86 September 2023 to August 2024.

87

88 **METHODS**

89 **Overview**

90 A static decision analytic model was developed in Microsoft Excel to estimate the number of
91 infections, hospitalizations, deaths, and costs associated with COVID-19 treatment over the
92 course of one year (September 2023-August 2024) for the Canadian population. The model
93 combined estimates of the incidence of COVID-19 in Canada, the effectiveness of updated

94 COVID-19 vaccinations and the probability of severe outcomes from COVID-19 infections. The
95 economic costs were estimated from both health care system and societal perspectives.
96 Outcomes estimated included the number of COVID-19 infections, hospitalization and deaths as
97 well as associated quality-adjusted life-years (QALYs) and costs.

98 The target population of this analysis was moderately to severely IC individuals in Canada aged
99 ≥ 18 years considered to be at increased risk of severe disease from COVID-19 as defined by the
100 National Advisory Committee on Immunization (NACI).²³

101 A Markov model with tunnel states was used to track the monthly COVID-19 vaccination status
102 of the target population, over a one-year analytic time horizon. At the start of the time horizon
103 (September 2023), the 2023 Canadian IC population aged ≥ 18 years was assigned to the
104 following historical vaccine coverage strata based on the highest level of prior COVID-19 vaccine
105 received: did not receive primary series; received primary series; received first booster; received
106 second booster. For historical vaccination coverage in the IC population, 3 doses (2 doses for
107 Ad26.COV2.S) were considered primary series.⁵ Additional doses were considered boosters.
108 Data on COVID-19 vaccine coverage in the IC population up to August 13, 2023 were obtained
109 from the Institute for Clinical Evaluative Sciences (ICES), which provided number of individuals in
110 priority groups vaccinated by dose, and risk conditions.²⁴ Risk conditions that matched the
111 Canadian Immunization Guide COVID-19 vaccine's criteria for moderate/severe IC were
112 included.⁵ The percentage of the IC population by age (18-59 years, ≥ 60 years) that received
113 primary series, 1 booster, or 2 boosters as their highest level of vaccination was calculated by
114 dividing the total number of IC individuals that received each level of vaccination by the total
115 number of IC individuals. The distribution of individuals, by age, and vaccination strata, are
116 displayed in Table 1.


117 **Table 1. Historical coverage in immunocompromised individuals, by highest level of**
118 **vaccination and age**

Age	Did not receive primary series	Received primary series only	Received first booster	Received second booster
18-59 years	41.9%	32.9%	17.9%	7.3%
60+ years	14.7%	21.2%	23.0%	41.1%

119
120 Individuals who had completed at least primary series vaccination were able to move to the Fall
121 2023 vaccination strata. The model simulation was run twice: once where those in the Fall 2023
122 vaccination strata receiving the Moderna Fall 2023 vaccine and once where they receive the
123 Pfizer-BioNTech Fall 2023 vaccine. The outcomes from each model run were compared.
124 The maximum Fall 2023 uptake was age-group specific and assumed to be the same as that
125 achieved by the general Canadian population for the COVID-19 second booster, as these were
126 the most complete data available.²⁵ Roll-out of the second booster was extremely staggered,
127 given timing of the second booster and 6 month recommended time interval between doses,
128 therefore uptake patterns from a shorter vaccine campaign was needed. Uptake was assumed to
129 occur over five months (September 2023-January 2024), as observed during the 2021-2022
130 seasonal influenza vaccination campaign.²⁶ Furthermore, the proportion of the total COVID-19
131 vaccinations that were administered each month was based on the monthly uptake rates
132 observed during the 2021-2022 influenza campaign.²⁶ The final uptake pattern by month and age
133 is displayed in Figure 1. Individuals receiving the Fall 2023 vaccine are drawn from each
134 vaccination strata proportionally. Optimistic scenario analyses were included where the uptake in

135 the 80+ years age group was increased from 73% to 80% (increase of 9%) and 95% (increase of
136 30%), with all other age group values adjusted up by the same multiplier.


137 **Figure 1. Fall 2023 COVID-19 vaccine uptake, by age group.**



138
139 The cohort begins the model in the Well health state (Figure 2). Each month, individuals are at
140 risk of COVID-19 symptomatic infection, which is dependent on infection incidence. The risk is
141 decreased by prior vaccination status, as well as whether they received the Fall 2023 vaccine. If
142 the individual develops a COVID-19 symptomatic infection, they move through an infection
143 consequence decision tree (Figure 3, described in detail further below), which calculates
144 subsequent costs and clinical outcomes of infection. Those with infections can remain in the
145 Well health state (shown as Recovered in the consequence decision tree), or transition to the
146 Dead health state (shown as In-Hospital Mortality in the decision tree). Death in the model is
147 only due to COVID-19 due to the short time horizon. All-cause mortality is not included.

148

149 **Figure 2. Model structure**




150

151 ^a see infection consequence decision tree structure (Figure 3)

152 ^b death due to COVID-19

153 **Figure 3. Infection consequence decision tree structure**



154

155 *risk of inpatient care dependent on vaccination status

156 ICU, intensive care unit

157

158

159 **Population size**

160 An IC population size of 894,580 was included in the analysis. This was estimated, by age group,
161 based on a US-based survey to determine the prevalence of immunocompromised individuals,²⁷
162 as well as a Statistics Canada survey conducted near the start of the COVID-19 pandemic to
163 determine the breakdown of the population by age.²⁸ Further details are provided in the
164 Supplementary Material.

165

166 **Incidence**

167 As the true incidence of COVID-19 infection in Canada is underestimated due to the lack of
168 mandatory testing and reporting, the infection incidence was calculated using Public Health
169 Agency of Canada (PHAC) COVID-19 hospitalization data for the general population for
170 September 2022 to August 2023.²⁹ Data collection for July and August 2023 were incomplete and
171 therefore, the ratio of the rates from June 2022 to June 2023 was applied to the rates from July
172 and August 2022 to approximate the hospitalization rates for July and August 2023.

173 The symptomatic infection incidence required to result in the predicted monthly rate of
174 hospitalizations was then back-calculated. To do this, calibration was performed using a version
175 of the Markov model populated with general population data, with the calibration target set to the
176 expected number of COVID-19 hospitalization data based on the data from PHAC. This method
177 estimated the monthly symptomatic infection incidence for September 2022 to August 2023. In
178 the base case analysis, it was then assumed that the COVID-19 incidence was the same for
179 September 2023-August 2024 as the prior year.

180 The projected monthly incidence rates of COVID-19 infection for September 2023-August 2024
181 and additional details are provided in the Supplementary Material.

182 **Residual vaccine effectiveness**

183 Residual VE is necessary to estimate the level of protection in the population entering the model
184 at the start of the analytic time horizon (September 1, 2023) due to prior vaccinations. This is
185 calculated using the timing of the prior boosters, VE of primary series and boosters against the
186 dominant variant at time of administration, and the historical coverage in the IC population.

187 The VE of primary series and monovalent boosters against Omicron BA.1/BA.2 for infection and
188 hospitalizations in the general population were obtained from the meta-analysis by Pratama et al.
189 (2022).³⁰ As there is a mix of primary series vaccines, the VE estimates for all vaccines were
190 used. For the VE of booster vaccination, results for mRNA vaccines were used. Primary and
191 booster monovalent VE against hospitalizations were further adjusted to account for the reduced
192 VE observed in the IC population and due to the emergence of BA.4/5 by using the ratio between
193 monovalent against omicron in the general population, and bivalent against BA.4/BA.5 in the IC
194 population.

195 Bivalent boosters (assumed to be first booster for some, and second booster for all in the IC
196 population) were available during the period of BA.4/5 dominance. The VE for bivalent boosters
197 against hospitalization in the IC population was obtained from a Kaiser Permanente study of the
198 Moderna bivalent vaccine (71.8%, 95% CI 48.8%-84.5%).¹⁰ As VE against infection was not
199 available for the IC population, it was assumed to be equivalent to monovalent vaccine against
200 Omicron (57.1% from Pratama et al., 2022^{30,31}) for the general population.

201 Monthly VE waning for primary series and boosters for both infection (4.8%) and hospitalization
202 (1.4%) were assumed to be the same monovalent booster waning rates estimated in the meta-
203 analysis by Higdon et al., (2022).³¹

204 Timing of prior boosters was obtained from coverage by week and age data from Public Health
205 Ontario.³² The month when 50% of vaccine were administered for primary series (Dec 2021), first

206 booster (May 2022 for those who received monovalent booster, November 2022 for those who
207 received bivalent booster), and second booster (November 2022, bivalent) for the oldest age
208 group was used as a proxy for vaccine administration date for each level of vaccination (primary
209 series, boosters).³² The timing of vaccine administration differed among age groups but this
210 simplifying assumption was adopted because the older age groups had significantly higher prior
211 coverage levels compared to younger age groups. Some IC individuals received monovalent and
212 some received bivalent vaccines as their second booster. Due to the difference in VE between
213 these two vaccine types, and timing of when administered, the residual VE of both were
214 calculated, then weighed by proportion that received each (60% received monovalent, and 40%
215 received bivalent as their second booster).³³ Those that received the second booster mainly
216 consisted of individuals aged 60+ that received a monovalent vaccine as their first booster earlier
217 in the year. It was assumed that the IC population completed the same level of vaccinations similar
218 to the general population, with the adjustment for the additional dose during primary series for the
219 IC population. The residual VE at start of the analytic time horizon is shown in Table 2.

220 **Table 2. Residual vaccine effectiveness in the immunocompromised population at start**
221 **of analytic time horizon**

	Infection	Severe
Completed primary series	0.0%	21.5%
Completed first booster	3.7%	53.2%
Completed second booster	9.3%	58.1%

222

223

224 **Vaccine effectiveness of the Moderna and Pfizer-BioNTech Fall 2023 vaccines**

225 Real world effectiveness on the Moderna and Pfizer-BioNTech Fall 2023 vaccines are not yet
226 available. Therefore, in the base case analysis, the vaccines are assumed to be well-matched to
227 the current variant, and are assumed to protect at the same level against the circulating dominant
228 variant as the bivalent booster (mRNA-1273.222 and BNT126b2 [WT/ OMI BA.4/BA.5]) protected
229 against BA.4/BA.5. Therefore, like the bivalent booster values used to calculate residual
230 effectiveness, the initial VE of the Moderna Fall 2023 vaccine was set to 71.8% for hospitalization
231 based on the Kaiser Permanente study of the Moderna bivalent vaccine,¹⁵ and 57.1% for infection,
232 based on the estimate for monovalent vaccine against Omicron from Pratama et al.³⁰ To
233 approximate the VE of a well-matched Pfizer-BioNTech Fall 2023 vaccine, the relative risk of
234 hospitalization and infection in the IC population for the Moderna bivalent booster compared to
235 the Pfizer-BioNTech bivalent booster (relative risk [RR] = 0.88 and 0.85, respectively) from Wang
236 et al., (2023) was applied to the assumed VEs for the Moderna Fall 2023 vaccine.²⁰ This resulted
237 in estimated initial VEs of 68.0% and 49.6%. The waning of the Fall 2023 vaccines were assumed
238 to be the same as the monovalent booster waning rates estimated in the meta-analysis by Higdon
239 et al., (2022).³¹ VE inputs for the base case and sensitivity analyses are summarized in Table 3.

240 **Table 3. Base case and sensitivity analyses vaccine effectiveness inputs**

Description of analysis	Moderna Fall 2023 vaccine				Pfizer-BioNTech Fall 2023 vaccine			
	Infection		Hospitalization		Infection		Hospitalization	
	Initial VE	Waning	Initial VE	Waning	Initial VE	Waning	Initial VE	Waning
Base case analysis	57.1%	4.8%	71.8%	1.4%	49.6%	4.8%	68.0%	1.4%
Sensitivity analysis: Moderna vaccine initial VE (95% CI)	30.6%, 83.7%	Equal to base case	48.8%, 84.5%	Equal to base case	18.3%, 80.8%	Equal to base case	41.8%, 82.4%	Equal to base case
Sensitivity analysis: RR 95% CI (Moderna vs. Pfizer-BioNTech vaccines) for initial VE	Equal to base case				42.8%, 55.8%	Equal to base case	64.3%, 70.9%	Equal to base case
Sensitivity analysis: Fall 2023 vaccine waning	Equal to base case	3.1%, 6.8%	Equal to base case	0.6%, 2.4%	Equal to base case	3.1%, 6.8%	Equal to base case	0.6%, 2.4%
Sensitivity analysis: differential waning for Moderna & Pfizer-BioNTech vaccines*	Equal to base case				Equal to base case	5.6%	Equal to base case	1.6%

241 *The monthly waning rate for the Pfizer-BioNTech vaccine was adjusted so that the relative risk of infection and
 242 hospitalization between Moderna and Pfizer-BioNTech vaccines (0.85 and 0.88, respectively) was maintained for each
 243 month of the time horizon.

244 VE: vaccine effectiveness; CI: confidence interval; RR: relative risk;

245 **Infection consequences decision tree**

246 The transition probabilities associated with the consequences of infection included in the infection
247 consequence decision tree (Figure 3), are summarized in Table 4. Input data were obtained from
248 targeted literature reviews and were estimated based on published sources, fee schedules, and
249 databases. Where available, Canadian sources and data were used.

250 Infected individuals either require hospitalization (inpatient care), or they do not. To inform the
251 risk of hospitalization in those without protection from COVID-19 vaccination, the model requires
252 the risk of hospitalization given infection in the unvaccinated population. As current Canadian data
253 are not disaggregated by vaccination status, the age-specific risk of hospitalization given infection
254 from the pre-vaccination period (July-December 2020) was first used and calculated from PHAC
255 data using number of infections and hospitalizations by age.³⁴ These data were then adjusted to
256 the omicron period using the RR (0.58) of hospitalization between the omicron and delta period
257 from a study by Wang et al., (2022).³⁵ These age-specific risks of hospitalization during omicron
258 given infection were then further adjusted to the immunocompromised population using the RR
259 (1.94) of hospitalization between moderately and severely immunocompromised individuals and
260 those not considered at high risk of severe outcomes during omicron, using data from a Canadian
261 study by Bahremand et al (2023).⁹ Final model inputs are displayed in Table 4.

262 Hospitalization stay is categorized by the highest level of care required (general ward, ICU without
263 ventilation, ICU with ventilation). The distribution, by age, were obtained from September 2022-
264 August 2023 PHAC data.²⁹ Deaths were only assumed to occur in those requiring hospitalization.
265 Probabilities of death for the general population in those hospitalized, by age, were calculating by
266 dividing the number of deaths by the number of hospitalizations from 2022-23 PHAC data.³⁶
267 These values were increased in the IC population for all ages by applying the odds ratio for
268 mortality between immunocompromised and immunocompetent individuals from Turtle et al.

269 (2023).⁸ As data were not disaggregated by hospital location of care, probabilities were assumed
270 to be the same for all.

271 All individuals with COVID-19 infection are subject to a “post-infection” cost and disutility toll
272 representing longer-term cost impacts.³⁷ As the “post-infection” costs and disutility represented
273 the average cost of all patients with a COVID-19 infection, it also included individuals who
274 developed long COVID. Therefore, long COVID was not represented separately in the model.

275

276 **Table 4. Base case infection consequences decision tree probabilities**

Age group	Hospitalization rates (unvaccinated) given infection, by age (%) ^{9,34,35*}	Hospitalization locations of care, by age (%) ²⁹			In-hospital mortality rates, by age ^{8,36†}
		No ICU or ventilation	ICU	ICU with ventilation	
18-19 years	0.5%	89.11%	5.41%	5.48%	1.08%
20-29 years	1.1%	91.81%	4.07%	4.12%	1.68%
30-39 years	2.1%	89.90%	5.02%	5.08%	2.56%
40-49 years	2.8%	86.32%	6.80%	6.88%	5.58%
50-59 years	4.9%	85.21%	7.35%	7.44%	6.98%
60-69 years	10.8%	86.51%	6.70%	6.79%	9.54%
70-79 years	24.8%	90.77%	4.59%	4.64%	12.19%
80+ years	30.1%	95.82%	2.08%	2.10%	20.64%

277 * Adjusted for Omicron³⁵ and immunocompromised status⁹

278 † Only applied to hospitalized patients

279 ICU: Intensive care unit

280

281

282 **Resource use and costs**

283 For the base case, resource use and costs associated with the treatment of infections and their
284 consequences are considered. As coverage in both comparator arms are expected to be the
285 same, and rates of adverse events are assumed to be similar and costs associated with adverse
286 events are also excluded. Therefore, only resource use and costs incurred due to the treatment
287 of COVID-19 infection (acute, post-infection, and from the societal perspective, productivity loss)
288 are included. Acute infection resource use includes non-hospitalized (emergency department and
289 physician visits) and hospitalizations due to acute infection.

290 Post-infection costs include ongoing care following the initial acute infection. Resource use was
291 based on a Canadian retrospective database study on individuals' post COVID-19 test. The
292 incremental resource use in those with positive tests were calculated by comparing use by those
293 with negatives tests, starting 56 days post test, and represented a year of resource use.³⁷
294 Incremental resource use included hospitalization, outpatient medical encounters, home care,
295 emergency department visits, and long-term care days. Costs for each resource were applied
296 based on standard fee schedules.³⁷

297 All costs were inflated to 2022 Canadian dollars using Statistics Canada's Consumer Price
298 Index.³⁸ Cost inputs from the health care perspective are displayed in Table 5. Societal cost
299 inputs are provided in the Supplementary Material.

300

301 **Table 5. Cost inputs**

Model parameter	Value	Assumptions
Short-term infection: non-hospitalized	\$111	Cost per outpatient visit ³⁹ and emergency department visits, ^{39,40} adjusted for average number of outpatient visit (0.34) and emergency department visit (0.25) per infection. ⁴¹
Hospitalization (per stay)		
No ICU or ventilation	\$19,484	Average cost April 2022-September 2022. ⁴² Cost for ICU with ventilation stay assumed same as ICU stay as data source did not differentiate the two.
ICU	\$54,672	
ICU with ventilation	\$54,672	
Post-Infection	\$513	Reported resource use, including average number of outpatient visits, hospitalization days, and long-term care days. ^{37-39,43} Not disaggregated by hospital status.
Quality-Adjusted Life-Years Lost		
Symptomatic infection, not hospitalized ^{44,45}	0.003	Applied to all symptomatic infections regardless of whether they were medically-attended or not.
Hospitalized, general ward ^{46,47}	0.008	The symptomatic infection, not hospitalized decrement is also added to the hospitalized
Hospitalized, ICU (no ventilator) ^{46,47}	0.016	

Hospitalized, ICU with ventilator ^{46,47}	0.030	values to reflect symptoms prior to hospitalization
Post-infection, not hospitalized ⁴⁸	0.0277	
Post-infection, hospitalized ⁴⁹	0.122	

302 ICU: Intensive care unit; QALY: quality-adjusted life-year

303

304 **Quality-adjusted life-years**

305 Infections, hospitalizations, post-infections, and death are all associated with quality-adjusted life-
306 year (QALY) decrements. The impact of the morbidity associated with COVID-19 infections is
307 captured as the QALY decrements provided in Table 5. The estimated number of life-years lost
308 due to premature COVID-19 mortality was calculated using the most recent Statistics Canada
309 data on life expectancy by age.⁵⁰ This was multiplied by the Canadian average population values
310 for QALYs experienced by age.⁵¹ All future QALYs were discounted to present value at rate of
311 1.5%.⁵²

312 **Scenario analyses and deterministic sensitivity analyses**

313 In addition to the scenario and sensitivity analyses previously mentioned, analyses were
314 conducted on incidence, hospitalization and mortality rates, costs, and QALY decrements. Where
315 available, lower and upper 95% confidence intervals were used. All other values were varied by
316 $\pm 25\%$. Value used for the included sensitivity analyses are presented in the Supplementary
317 Material.

318

319

320 **RESULTS**

321 In the base case analysis, assuming an IC population size of 894,580, there is expected to be
322 65,536 symptomatic infections, 7,151 hospitalizations and 1,133 deaths when vaccinating the
323 Canadian IC adult population with the Moderna Fall 2023 vaccine from September 2023 – August
324 2024. This was achieved with 359,067 vaccinations administered between September 2023-
325 January 2024. Given the expected lower VE of the Pfizer-BioNTech vaccine, the Moderna vaccine
326 is expected to prevent 2,411 infections (3.5%), 275 hospitalizations (3.7%), and 47 deaths (4.0%)
327 compared to vaccinating with Pfizer-BioNTech. Additionally, 330 more QALYs would be gained
328 with the Moderna Fall 2023 vaccine, with over half being attributed to the prevention of death
329 (Table 6). From the health care perspective, the prevented infections and hospitalizations with
330 use of the Moderna Fall 2023 vaccine results in a \$7.4 million saved in treatment costs; when
331 productivity losses are included, \$8.3 million in treatment cost savings are realized.

332

333 **Table 6. Base case results**

	Moderna Fall 2023 vaccine	Pfizer-BioNTech Fall 2023 vaccine	Difference*
Clinical Outcomes			
Number of vaccinations	359,067	359,067	0
Cases			
Symptomatic infections	65,585	67,996	-2,411
Hospitalizations	7,151	7,426	-275
COVID-19 related deaths	1,133	1,180	-47
QALYs lost			
Morbidity	2,587	2,682	-96
Mortality	6,457	6,692	-235
Total QALYS lost	9,044	9,374	-330
Economic Outcomes			
Short-term infection costs	\$164,397,246	\$170,630,436	-\$6,233,190
Post-infection period	\$33,054,168	\$34,266,464	-\$1,212,296
Total Health care perspective	\$197,451,414	\$204,896,900	-\$7,445,486
Productivity loss	\$39,488,494	\$40,338,892	-\$850,397
Total societal perspective	\$236,939,908	\$245,235,792	-\$8,295,884

334 *Moderna Fall 2023 vaccine- Pfizer-BioNTech Fall 2023 vaccine

335 QALY: quality-adjusted life-year

336


337 Results from scenario analyses on incidence and vaccine uptake continued to find treatment cost
 338 savings and QALYs saved with the Moderna Fall 2023 vaccine compared to the Pfizer-BioNTech
 339 vaccine. When the incidence of COVID-19 infection was increased or decreased, the difference
 340 between the Moderna and Pfizer-BioNTech Fall vaccines for outcomes were increased or

341 decreased by the same percentage. Increasing the Fall 2023 vaccine uptake in those aged 80
342 years and older to 80% increased costs saved and QALYs gained by the Moderna Fall vaccine
343 compared to the Pfizer-BioNTech version by 9%, and increasing the uptake to 95% increased the
344 costs saved and QALYs gained by 30%, as more IC individuals are vaccinated, and therefore
345 contributing to the predicted benefits. Sensitivity analyses are presented in Figure 4. Tornado
346 diagrams summarizing the sensitivity analyses for both costs saved and QALYs gained with the
347 Moderna Fall vaccine compared to the Pfizer-BioNTech Fall vaccine are displayed. For ease of
348 comparison, parameters for both diagrams are listed in decreasing order according to differences
349 in cost saved. Parameters that did not have an impact on outcomes were excluded from the
350 diagrams. In the base case, the starting VE against infection and hospitalization for Pfizer-
351 BioNTech were calculated using the Wang et al. RRs,²⁰ and the same waning rates were then
352 applied to both vaccines. Costs and QALYs were most sensitivity to changes where the RR of
353 infection and hospitalization was maintained between both vaccines for the entire analytic time
354 horizon, by adjusting the waning rate of Moderna and Pfizer-BioNTech vaccines upward. This
355 resulted in faster waning rates for the Pfizer-BioNTech vaccine. Next, model outcomes were
356 sensitivity to the RR for infection and hospitalizations between the vaccines, with higher RRs
357 resulting in lower costs and QALYs saved, and vice versa. The Moderna Fall vaccine initial VE
358 was also a driver of costs and QALYs, with higher initial VEs resulting in smaller VE differences
359 between the vaccines, and therefore a smaller difference in outcomes.


360

361 **Figure 4. Sensitivity analyses tornado diagrams: cost and QALYs**

362



363



364

365 CI: confidence interval; UB: upper bound; LB: lower bound; RR: relative risk; ICU: intensive care unit; QALY: quality-
 366 adjusted life-year

367

368

369 **DISCUSSION**

370 This study estimated the difference in number of infections, hospitalization and death in the
371 Canadian IC population over a one-year time horizon, with Moderna updated Fall 2023 vaccine
372 administration compared to Pfizer-BioNTech updated Fall 2023 vaccine administration. Given the
373 higher predicted VE of the Moderna Fall 2023 vaccine compared to the Pfizer-BioNTech vaccine,
374 in a population size of 894,580 IC adults, vaccinating with the Moderna vaccine is predicted to
375 prevent an additional 2,411 infections, 275 hospitalizations and 47 deaths, resulting in \$7.4 million
376 in health care cost savings, while gaining 330 QALYs. If productivity loss is included, the cost
377 saving could be \$8.3 million over the one-year time horizon.

378 The model is a simplification of the effects of vaccination on a population. It only accounts for
379 direct protection of those receiving the vaccine, and only included the population of interest. It
380 does not account for indirect protection through decreasing transmission in the general
381 population. However, as the IC population is only a small sub-set of the entire Canadian
382 population, vaccinating these individuals is unlikely to impact transmission in the general
383 population.^{53,54}

384 The SARS-CoV-2 virus is constantly evolving, and there is high uncertainty around future variants
385 and incidence, and how responsive vaccines will be. Furthermore, as in many countries, many
386 individuals no longer seek a medical diagnosis for their symptoms and there is under-reporting of
387 COVID-19 infections in Canada. However, using the most recent information available on
388 hospitalizations, we predicted the possible infection incidence for September 2022 to August
389 2023. We assumed that the incidence of infection for September 2023 to August 2024 will be the
390 same as the previous year, however, it is impossible to know how COVID-19 will behave in this
391 new post-pandemic era. The incidence of COVID-19 infection was calculated from the general
392 population. While the IC population is at higher risk for more severe outcomes if they develop an

393 infection, it is not known if the incidence of infection is different from the general population. As
394 static models are linear by definition, a linear impact is seen on many parameters. For example,
395 in the scenario analyses where incidence was increased/decreased by 25%, differences between
396 the arms for costs saved and QALYs gained also increased/decreased by 25%.

397 Model results are highly sensitive to VE values of the Moderna and Pfizer-BioNTech Fall vaccines.
398 While it is true that the VE values used in this analysis are assumptions and not based on real
399 world data of the current XBB1.5 version of the vaccine, robust immunological response are
400 induced by the vaccines and were in the same magnitude of increase compared to previous
401 formulations against the intended variants.⁵⁵ Therefore, the estimate of the Fall 2023 vaccines
402 are based on real world data on previous versions of each vaccine. Despite the overall median
403 follow-up duration of 2.46 months, VE estimates against hospitalization from Tseng et al., (2023)
404 were used as it provided Moderna vaccine specific estimates during the time of BA.4/BA.5
405 dominance. This is in alignment with other modeling approaches.⁵⁶ Previous studies have found
406 higher VE values with Moderna vaccines compared to the Pfizer-BioNTech counterpart,^{11-15,20}
407 including in other vulnerable populations, such as residents in nursing and retirement homes.⁵⁷

408 The data used in this analysis to estimate Pfizer-BioNTech Fall 2023 vaccine VEs were obtained
409 from a meta-analysis, which is considered the highest level of evidence in evidence-based
410 medicine.⁵⁸ Difference in the VEs between the vaccines may be due in part to different
411 formulation, dosage, and delivery system.²⁰ In their Communicable Disease Control Manual, The
412 British Columbia Centre for Disease Control lists the Moderna Fall 2023 vaccine as the preferred
413 vaccine over the Pfizer-BioNTech version for IC individuals due to its potentially greater immune
414 response,⁹ which is correlated with VE.^{59,60} If we expect similar VE outcomes as in previous
415 version of the vaccine, then we can expect fewer infections, hospitalizations and deaths and lower
416 COVID-19 treatment costs with the Moderna updated Fall 2023 vaccine.

417 Although there are study limitations due the lack of IC specific data, steps have been taken to
418 adjust existing general population data, and determine the impact of uncertainty. Because data
419 were unavailable on the VE against infection of prior Moderna formulations in the IC population,
420 or on the relative VE for the general population compared to the IC population, we were unable
421 to estimate the adjusted VE against infection for the Moderna updated Fall 2023 vaccine from the
422 same source used to estimate the VE against hospitalization, and assumed the same VE against
423 infection as mRNA-1273 against BA.1/BA.2 in the general population.³⁰ Although different
424 populations and time periods were used, the VE estimate against infection is conservative. If the
425 VE of the Moderna updated Fall 2023 vaccine against infection was assumed to be lower in the
426 IC population, then the estimated number of infections prevented compared to the Pfizer-
427 BioNTech vaccine would be even larger (see Supplementary Material for results).

428 The population size was estimated using proportion estimated from the US, as suitable data were
429 not available from Canada. Over or underestimating the population size will result in the total
430 costs saved and QALYs gained to be over or underestimated, respectively.

431 Additionally, monthly VE waning rates were obtained from the general population. A study by
432 Ferdinand et al. (2022), reported higher hospitalization waning rates over a six-month period in
433 IC individuals during Delta/Omicron predominance.⁶¹ However, increasing the waning rates in
434 sensitivity analysis had minimal effects on cost and QALYs as the waning rate was the same for
435 both the Moderna and Pfizer-BioNTech Fall 2023 vaccines.

436 Although hospitalization and mortality rates were used for the Canadian general population,
437 efforts were made to adjust these to the IC population by applying the increased risk observed in
438 the IC population compared to immunocompetent individuals. In all sensitivity analyses
439 surrounding these parameters, the Moderna Fall 2023 vaccine continued to result in cost savings
440 and QALYs gained compared to the Pfizer-BioNTech Fall vaccine. Additionally, QALYs related to

441 COVID-19 infection and hospitalizations were based on the general population, and were not
442 adjusted due to lack of data. However, varying these values in sensitivity analyses had minimal
443 impact on total QALYs gained.

444 The proportion of hospitalized IC individuals that required ICU admission was based on the
445 general population data as Canadian data on the IC population was not available. However, a UK
446 study by Evans et al., (2023) found the 2.8-4.7% of hospitalized IC individuals in 2022 required
447 ICU admission compared to 2.1% overall. Based on PHAC data, the age-dependent rate of ICU
448 admission given hospitalizations in the general population between July 2022-August 2023
449 ranged from 4.2%-10.9%. Although the UK and Canadian populations included are not
450 comparable, the UK study suggests that there may be a higher proportion of ICU admissions in
451 hospitalized patients compared to the general population. As such, given that the Moderna Fall
452 2023 vaccine is predicted to result in fewer hospitalization compared to the Pfizer-BioNTech Fall
453 2023 vaccine, the cost savings and QALYs estimated by the current study is likely to be
454 underestimated.

455 Likewise, resource use and costs included in the analyses were obtained from the general
456 population, and not IC individuals, resulting in conservative estimates. Preliminary findings
457 comparing the two populations found that in the US, IC individual COVID-19 inpatient
458 expenditures were 1.4 times greater than non-IC individuals.⁶² If healthcare expenditures up to
459 60 days post discharge were included, this value increases to 1.8 times greater. While the US
460 and Canadian health care systems and costing are not comparable, this study provides evidence
461 that IC individuals may require a higher volume of health care, and that the cost inputs used in
462 the current analysis may therefore be underestimated. Increasing these cost inputs would
463 increase the cost savings by the Moderna Fall 2023 vaccine compared to the Pfizer-BioNTech
464 vaccine, as confirmed in the cost sensitivity analyses. Therefore, the limitations in resource use

465 and cost values used in the base case result in extremely conservative estimates of the costs
466 saved by use of the Moderna Fall 2023 vaccine.

467 Various other sensitivity analyses were conducted on the VE estimates, including the difference
468 in VE between the vaccines, and varying the monthly waning rate. Still, in every analysis, overall
469 results remained the same, with the Moderna Fall 2023 vaccine saving costs and gaining QALYs
470 compared to the Pfizer-BioNTech Fall 2023 vaccine. Cost savings varied from \$1.6 million, where
471 the relative risk of infection or hospitalizations between the two vaccines was closer to 1, resulting
472 in a smaller difference in VE values, to \$28.1 million, when the waning rate of Pfizer-BioNTech
473 was set higher. QALYs gained ranged from 71 to 1,227 (resulting from same sensitivity analyses
474 mentioned for cost savings). These findings were largely driven by the changes in the number of
475 hospitalizations.

476 The model only allowed those who completed primary series vaccination to receive a Fall 2023
477 vaccine, as was the case for the bivalent booster. The current NACI guidelines recommend the
478 XBB.1.5-containing formulations for those previously vaccinated. As the vaccines are also
479 authorized by Health Canada for those not previously vaccinated, NACI states that they may be
480 used to initiate primary series. However, recommendations for this population will be forthcoming
481 in the next months.² Additionally, as the historical ICES database coverage data from ICES found
482 that only 15% of IC individuals aged 60 and above did not complete primary series,²⁴ it is unlikely
483 that vaccination of a small proportion of individuals with primary series would change model
484 results. Saskatchewan has indicated that moderately to severely IC individuals who have not
485 received primary series be vaccinated with multiple doses of the Fall 2023 vaccines, with
486 immunocompetent individuals requiring one.⁶³

487 In conclusion, this study conservatively estimated the potential benefits of vaccinating the
488 Canadian IC adult population with the Moderna updated Fall 2023 vaccine instead of the Pfizer-

489 BioNTech Fall 2023 vaccine. If the Moderna and Pfizer-BioNTech Fall 2023 vaccines are well-
490 matched to the dominant variants and protect against infection and hospitalizations similar to
491 previous versions of the vaccines, using the Moderna Fall 2023 vaccine could result in
492 substantial health care and societal cost savings, as well as QALYs gained.

493 **REFERENCES**

494

495 1. World Health Organization (WHO). Statement on the fifteenth meeting of the IHR (2005)
496 Emergency Committee on the COVID-19 pandemic. Updated May 5, 2023. Accessed
497 October 2, 2023.

498 2. National Advisory Committee on Immunization (NACI). An Advisory Committee Statement
499 (ACS). Addendum on the guidance on the use of COVID-19 vaccines in the fall of 2023.
500 September 12, 2023. [https://www.canada.ca/content/dam/phac-](https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-addendum-guidance-use-covid-19-vaccines-fall-2023/statement.pdf)
501 [aspc/documents/services/publications/vaccines-immunization/national-advisory-](https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-addendum-guidance-use-covid-19-vaccines-fall-2023/statement.pdf)
502 [committee-immunization-addendum-guidance-use-covid-19-vaccines-fall-](https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-addendum-guidance-use-covid-19-vaccines-fall-2023/statement.pdf)
503 [2023/statement.pdf](https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-addendum-guidance-use-covid-19-vaccines-fall-2023/statement.pdf). Accessed September 14, 2023.

504 3. Government of Canada. COVID-19 signs, symptoms and severity of disease: a clinician
505 guide. Updated June 1, 2022. [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html#a3)
506 [health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html#a3)
507 [symptoms-severity.html#a3](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html#a3). Accessed September 14, 2023.

508 4. Bertini CD, Jr., Khawaja F, Sheshadri A. Coronavirus Disease-2019 in the
509 Immunocompromised Host. *Clin Chest Med.* 2023;44(2):395-406.

510 5. Public Health Agency of Canada. Canadian Immunization Guide. COVID-19 vaccines.
511 [https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html)
512 [immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html). Updated
513 September 12, 2023. Accessed September 14, 2023.

514 6. Antinori A, Bausch-Jurken M. The Burden of COVID-19 in the Immunocompromised
515 Patient: Implications for Vaccination and Needs for the Future. *J Infect Dis.*
516 2023;228(Suppl 1):S4-s12.

-
- 517 7. Singson JRC, Kirley PD, Pham H, et al. Factors Associated with Severe Outcomes Among
518 Immunocompromised Adults Hospitalized for COVID-19 - COVID-NET, 10 States, March
519 2020-February 2022. *MMWR Morbidity and mortality weekly report*. 2022;71(27):878-884.
- 520 8. Turtle L, Thorpe M, Drake TM, et al. Outcome of COVID-19 in hospitalised
521 immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective
522 cohort study. *PLoS Med*. 2023;20(1):e1004086.
- 523 9. Bahremand T, Yao JA, Mill C, Piszczek J, Grant JM, Smolina K. COVID-19
524 hospitalisations in immunocompromised individuals in the Omicron era: a population-
525 based observational study using surveillance data in British Columbia, Canada. *The
526 Lancet Regional Health - Americas*. 2023;20:100461.
- 527 10. Tseng H, Ackerson BK, Sy LS, et al.,. Effectiveness of mRNA-1273 bivalent (Original and
528 Omicron BA.4/BA.5) COVID-19 vaccine in preventing hospitalizations for COVID-19,
529 medically attended SARS-CoV-2 infections, and hospital death in the United States.
530 *medRxiv*. 2023.
- 531 11. Nguyen VH BC, Bogdanov A, et al. Relative effectiveness of BNT162b2, mRNA-1273,
532 and Ad26.COV2.S vaccines and homologous boosting in preventing COVID-19 in adults
533 in the US. *medRxiv*. 2023.
- 534 12. Ono S, Michihata N, Yamana H, et al. Comparative Effectiveness of BNT162b2 and
535 mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron
536 Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Registries
537 in Japan. *Clin Infect Dis*. 2023;76(1):18-24.
- 538 13. Mayr FB TV, Shaikh OS, et al.,. Comparative COVID-19 Vaccine Effectiveness Over Time
539 in Veterans. *Open Forum Infect Dis*. 2022;9(7).

-
- 540 14. Hulme WJ, Horne EMF, Parker EPK, et al. Comparative effectiveness of BNT162b2
541 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in
542 OpenSAFELY-TPP. *BMJ*. 2023;380:e072808.
- 543 15. Kopel H, Nguyen VH, Boileau C, et al. (in press.) Comparative effectiveness of Bivalent
544 (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and
545 BNT162b2 Bivalent Vaccine in Adults in the US. *Vaccines*.
- 546 16. Moderna Inc. SPIKEVAX (mRNA-1273) Full Prescribing Information. 2022.
- 547 17. Pfizer/BioNTech. COMIRNATY (BNT162b2) Full Prescribing Information. 2022.
- 548 18. Moderna Inc. Fact sheet for healthcare providers administering vaccine: emergency use
549 authorization of Moderna Covid-19 vaccine, bivalent (original and omicron ba.4/ba.5). .
550 Moderna, Inc. [https://eua.modernatx.com/covid19vaccine-eua/eua-fact-sheet-](https://eua.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf)
551 [providers.pdf](https://eua.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf). Accessed August 25, 2023.
- 552 19. Pfizer/BioNTech. Fact sheet for healthcare providers administering vaccine: emergency
553 use authorization (EUA): Pfizer-BioNTech COVID-19 vaccine, bivalent (original and
554 omicron BA.4/BA.5) and booster dose for 12 years of age and older (2022).
555 Pfizer/BioNTech. <https://www.fda.gov/media/167211/download>. Accessed March 7, 2023.
- 556 20. Wang X, Haeussler K, Spellman A, et al. Comparative effectiveness of mRNA-1273 and
557 BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review
558 and meta-analysis using the GRADE framework. *Frontiers in Immunology*. 2023;14.
- 559 21. Government of Canada. Health Canada authorizes Moderna COVID-19 vaccine targeting
560 the Omicron XBB.1.5 subvariant. September 12, 2023. [https://www.canada.ca/en/health-](https://www.canada.ca/en/health-canada/news/2023/09/health-canada-authorizes-moderna-covid-19-vaccine-targeting-the-omicron-xbb15-subvariant.html)
561 [canada/news/2023/09/health-canada-authorizes-moderna-covid-19-vaccine-targeting-](https://www.canada.ca/en/health-canada/news/2023/09/health-canada-authorizes-moderna-covid-19-vaccine-targeting-the-omicron-xbb15-subvariant.html)
562 [the-omicron-xbb15-subvariant.html](https://www.canada.ca/en/health-canada/news/2023/09/health-canada-authorizes-moderna-covid-19-vaccine-targeting-the-omicron-xbb15-subvariant.html). . Accessed September 14, 2023.
- 563 22. Health Canada. Health Canada authorizes Pfizer-BioNTech COVID-19 vaccine targeting
564 the Omicron XBB.1.5 subvariant. <https://www.canada.ca/en/health->

-
- 565 [canada/news/2023/09/health-canada-authorizes-pfizer-biontech-covid-19-vaccine-](https://www.canada.ca/en/public-health/news/2023/09/health-canada-authorizes-pfizer-biontech-covid-19-vaccine-targeting-the-omicron-xbb15-subvariant.html)
566 [targeting-the-omicron-xbb15-subvariant.html](https://www.canada.ca/en/public-health/news/2023/09/health-canada-authorizes-pfizer-biontech-covid-19-vaccine-targeting-the-omicron-xbb15-subvariant.html). Accessed September 29, 2023.
- 567 23. Government of Canada. COVID-19 vaccines; Canadian immunization guide. Last partial
568 content update: June 27, 2023. [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a6.4.considerations)
569 [health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a6.4.considerations)
570 [vaccines/page-26-covid-19-vaccine.html#a6.4.considerations](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a6.4.considerations). Accessed September 14,
571 2023.
- 572 24. Institute for Clinical Evaluative Sciences (ICES). ICES COVID-19 Dashboard. Vaccine
573 Coverage by Priority Groups. Accessed August 22, 2023.
- 574 25. Public Health Agency of Canada. COVID-19 vaccination: Vaccination coverage.
575 <https://health-infobase.canada.ca/covid-19/vaccination-coverage/>. Accessed August 22,
576 2023.
- 577 26. Public Health Agency of Canada. Seasonal Influenza Vaccination Coverage in Canada,
578 2021-2022. [https://www.canada.ca/en/public-health/services/immunization-](https://www.canada.ca/en/public-health/services/immunization-vaccines/vaccination-coverage/seasonal-influenza-survey-results-2021-2022/full-report.html)
579 [vaccines/vaccination-coverage/seasonal-influenza-survey-results-2021-2022/full-](https://www.canada.ca/en/public-health/services/immunization-vaccines/vaccination-coverage/seasonal-influenza-survey-results-2021-2022/full-report.html)
580 [report.html](https://www.canada.ca/en/public-health/services/immunization-vaccines/vaccination-coverage/seasonal-influenza-survey-results-2021-2022/full-report.html). Published 2023. Accessed September 18, 2023.
- 581 27. Harpaz R, Dahl RM, Dooling KL. Prevalence of Immunosuppression Among US Adults,
582 2013. *JAMA*. 2016;316(23):2547-2548.
- 583 28. Statistics Canada. Health-related concerns and precautions during the COVID-19
584 pandemic: a comparison of Canadians with and without underlying health concerns. July
585 2, 2020. . [https://www150.statcan.gc.ca/n1/en/pub/82-003-x/2020005/article/00001-](https://www150.statcan.gc.ca/n1/en/pub/82-003-x/2020005/article/00001-eng.pdf?st=fRIC98Ej)
586 [eng.pdf?st=fRIC98Ej](https://www150.statcan.gc.ca/n1/en/pub/82-003-x/2020005/article/00001-eng.pdf?st=fRIC98Ej). Accessed April 21, 2023.
- 587 29. Public Health Agency of Canada. COVID-19 epidemiology update: Current situation.
588 Hospital use. September 2022-August 2023. [https://health-infobase.canada.ca/covid-](https://health-infobase.canada.ca/covid-19/current-situation.html#graphHospVentICU)
589 [19/current-situation.html#graphHospVentICU](https://health-infobase.canada.ca/covid-19/current-situation.html#graphHospVentICU). Accessed September 5, 2023.

-
- 590 30. Pratama NR, Wafa IA, Budi DS, et al. Effectiveness of COVID-19 Vaccines against SARS-
591 CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-
592 Regression. *Vaccines*. 2022;10(12):2180.
- 593 31. Higdon MM, Baidya A, Walter KK, et al. Duration of effectiveness of vaccination against
594 COVID-19 caused by the omicron variant. *The Lancet Infectious diseases*.
595 2022;22(8):1114-1116.
- 596 32. Public Health Ontario. Ontario Respiratory Virus Tool.
597 [https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-](https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool)
598 [Virus-Tool](https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool). Accessed September 13, 2023.
- 599 33. Government of Canada. COVID-19 vaccination: doses administered. [https://health-](https://health-infobase.canada.ca/covid-19/vaccine-administration/)
600 [infobase.canada.ca/covid-19/vaccine-administration/](https://health-infobase.canada.ca/covid-19/vaccine-administration/). Published 2023. Accessed July 20,
601 2023, 2023.
- 602 34. Public Health Agency of Canada. COVID-19 epidemiology update: current situation.
603 Cases and hospitalizations July - December 2020. [https://health-](https://health-infobase.canada.ca/covid-19/current-situation.html#graphHospVentlCU)
604 [infobase.canada.ca/covid-19/current-situation.html#graphHospVentlCU](https://health-infobase.canada.ca/covid-19/current-situation.html#graphHospVentlCU). Accessed April
605 27, 2023.
- 606 35. Wang L, Berger N, Kaelber D, Davis P, Volkow N, Xu R. COVID infection rates, clinical
607 outcomes, and racial/ethnic and gender disparities before and after Omicron emerged in
608 the US. *medRxiv*. 2022;2022.02.21.22271300.
- 609 36. Public Health Agency of Canada. COVID-19 epidemiology update: Current situation:
610 National and regional trends. [https://health-infobase.canada.ca/covid-19/current-](https://health-infobase.canada.ca/covid-19/current-situation.html#graphHospVentlCU)
611 [situation.html#graphHospVentlCU](https://health-infobase.canada.ca/covid-19/current-situation.html#graphHospVentlCU). Accessed September 5, 2023.
- 612 37. McNaughton CD, Austin PC, Sivaswamy A, et al. Post-acute health care burden after
613 SARS-CoV-2 infection: a retrospective cohort study. *Cmaj*. 2022;194(40):E1368-e1376.

-
- 614 38. Statistics Canada. Consumer Price Index, annual average, not seasonally adjusted. Table
615 19-10-0005-01. <https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1810000501>.
616 Accessed April 26, 2023.
- 617 39. Ontario Ministry of Health. Schedule of Benefits. Physician Services Under the Health
618 Insurance Act (June 29, 2023 (effective July 24, 2023)).
619 https://health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master.pdf. Accessed
620 September 5, 2023.
- 621 40. Government of Alberta. Alberta Interactive Health Data Application. Hospital
622 Ambulatpopy Care Case Costs - CACS - 2019 version. Acute upper respiratory.
623 http://www.ahw.gov.ab.ca/IHDA_Retrieval/selectSubCategoryParameters.do. Accessed
624 April 23, 2023.
- 625 41. Huang BZ, Creekmur B, Yoo MS, Broder B, Subject C, Sharp AL. Healthcare Utilization
626 Among Patients Diagnosed with COVID-19 in a Large Integrated Health System. *J Gen
627 Intern Med.* 2022;37(4):830-837.
- 628 42. Canadian Institute for Health Information. COVID-19 hospitalization and emergency
629 department statistics. [https://www.cihi.ca/en/covid-19-hospitalization-and-emergency-
630 department-statistics](https://www.cihi.ca/en/covid-19-hospitalization-and-emergency-department-statistics). Accessed April 18, 2023.
- 631 43. Canadian institute for Health Information. Trends in Hospital Spending, 2005-2006 to
632 2020-2021 - Data Tables - Series C: Average Direct Cost per Patient by Selected
633 Functional Centre. [https://www.cihi.ca/en/trends-in-hospital-spending-2005-2006-to-
634 2020-2021-data-tables-series-c-average-direct-cost-per](https://www.cihi.ca/en/trends-in-hospital-spending-2005-2006-to-2020-2021-data-tables-series-c-average-direct-cost-per). Accessed April 26, 2023.
- 635 44. Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. *The
636 American journal of medicine.* 2002;113(4):300-307.

-
- 637 45. Centers for Disease Control and Prevention. Isolation and Precautions for People with
638 COVID-19. <https://www.cdc.gov/coronavirus/2019-ncov/your-health/isolation.html>.
639 Accessed December 21, 2022.
- 640 46. Barbut F, Galperine T, Vanhems P, et al. Quality of life and utility decrement associated
641 with *Clostridium difficile* infection in a French hospital setting. *Health and quality of life*
642 *outcomes*. 2019;17(1):6.
- 643 47. Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized
644 COVID-19 patients in the United States. *J Med Econ*. 2021;24(1):308-317.
- 645 48. Sandmann FG, Tessier E, Lacy J, et al. Long-Term Health-Related Quality of Life in Non-
646 Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute
647 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal
648 Analysis and Cross-Sectional Comparison With Controls. *Clin Infect Dis*.
649 2022;75(1):e962-e973.
- 650 49. The PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation
651 profiling of long COVID and association with 1-year recovery following hospitalisation in
652 the UK: a prospective observational study. *Lancet Respir Med*. 2022;10:761-775.
- 653 50. Statistics Canada. Table 13-10-0837-01. Life expectancy and other elements of the
654 complete life table, single-year estimates, Canada, all provinces except Prince Edward
655 Island. <https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310083701>. Accessed
656 September 8, 2023.
- 657 51. Guertin JR, Feeny D, Tarride JE. Age- and sex-specific Canadian utility norms, based on
658 the 2013-2014 Canadian Community Health Survey. *Cmaj*. 2018;190(6):E155-e161.
- 659 52. CADTH. *Guidelines for the economic evaluation of health technologies: Canada*. Ottawa
660 March 2017.

-
- 661 53. WHO guide for standardization of economic evaluations of immunization programmes,
662 2nd edition. Geneva: World Health Organization; 2019.
- 663 54. Public Health Agency of Canada. *National Advisory Committee on Immunization (NACI)*
664 *Guidelines for the Economic Evaluation of Vaccination Programs in Canada*. April 2023.
- 665 55. FDA U.S. Food & Drug Administration. Vaccines and Related Biological Products Advisory
666 Committee. Moderna COVID-19 Variant Vaccines. Moderna, Inc. June 15, 2023.
667 <https://www.fda.gov/media/169539/download>. Accessed October 10, 2023.
- 668 56. Kohli M, Maschio M, Joshi K, et al. (in press) The potential clinical impact and cost-
669 effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.
670 *Journal of Medical Economics*.
- 671 57. Breznik JA, Rahim A, Kajaks T, et al. Protection from Omicron Infection in Residents of
672 Nursing and Retirement Homes in Ontario, Canada. *J Am Med Dir Assoc*. 2023;24(5):753-
673 758.
- 674 58. Cochrane UK. Meta-analysis: what, why and how. [https://uk.cochrane.org/news/meta-](https://uk.cochrane.org/news/meta-analysis-what-why-and-how)
675 [analysis-what-why-and-how](https://uk.cochrane.org/news/meta-analysis-what-why-and-how). Accessed October 11, 2023.
- 676 59. Cromer D, Steain M, Reynaldi A, et al. Predicting vaccine effectiveness against severe
677 COVID-19 over time and against variants: a meta-analysis. *Nat Commun*.
678 2023;14(1):1633.
- 679 60. Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of
680 protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis.
681 *Lancet Microbe*. 2022;3(1):e52-e61.
- 682 61. Ferdinands JM, Rao S, Dixon BE, et al. Waning of vaccine effectiveness against moderate
683 and severe covid-19 among adults in the US from the VISION network: test negative,
684 case-control study. *BMJ*. 2022;379:e072141.

-
- 685 62. Zurovac J, Barna M. mRNA-1273 vaccinated expenditure of hospitalisation analysis
686 results. 03NOV2023. Moderna data on file.
- 687 63. Saskatchewan Ministry of Health. COVID-19 Vaccine Guidance.
688 [https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/C](https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19_vaccine_administration.pdf)
689 [OVID-19 vaccine administration.pdf](https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19_vaccine_administration.pdf). Published 2023. Updated October 6, 2023. Accessed
690 October 19, 2023.

691 **Declarations**

692 Ethics approval and consent to participate: Not applicable

693 Consent for publication: Not applicable

694 Availability of data and materials: The datasets used and/or analyzed during the current study
695 are available from the corresponding author on reasonable request.

696 Competing interests: EB, KaJ, KeJ, and NV are employees of Moderna, Inc and may hold
697 shares and stock options in Moderna, Inc. MK is a shareholder in Quadrant Health Economics,
698 Inc., which was contracted by Moderna, Inc. to conduct this study. KF, AL, and MM are
699 consultants at Quadrant Health Economics Inc.

700 Funding: This study was funded by Moderna, Inc., Cambridge, MA, USA.

701 Authors' contributions: Conceptualization, AL, MK, MM, KaJ, NV; Methodology, AL, KaJ, MK,
702 MM, EB, and NV; Software, MM; Validation, AL and MK; Formal Analysis, AL and KF; Writing –
703 Original Draft Preparation, AL and MK; Writing – Review & Editing, KaJ, KeJ, EB, NV; Funding
704 Acquisition, KaJ, EB, NV

705 Acknowledgements: Not applicable

706 Author's information (optional): Not applicable